A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironmentsKevin C. Barry, Matthew F. Krummel, Joy Hsu et al.|Nature Medicine|2018Cited by 1k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher Garris, Mikaël J. Pittet, Sean P. Arlauckas et al.|Immunity|2018Cited by 937
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil Daud, Omid Hamid|Journal of Clinical Oncology|2016Cited by 674
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell ImmunityMikhail Binnewies, Matthew F. Krummel, Adriana M. Mujal et al.|Cell|2019Cited by 617
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV MelanomaAxel Hauschild, Ulrich Keilholz, Sanjiv S. Agarwala et al.|Journal of Clinical Oncology|2009Cited by 545